Type6 Therapeutics is redefining precision medicine by pioneering a new class of kinase inhibitors that address some of the biggest challenges in targeted drug development: toxicity from poor selectivity, cancer-protective signaling, and acquired resistance.

Rather than jamming disease-driving kinases in their active (ON) state—as most drugs do—Type6’s platform taps into nature’s own regulation system by switching kinases OFF entirely. This OFF-state, while therapeutically powerful, has remained virtually undruggable—until now.

Leveraging breakthroughs in computational biology, multivalent chemistry, and allostery-aware drug design, Type6 has developed a platform that can "staple down" kinases into their OFF configuration. This unlocks access to previously hidden pockets of the human kinome, opening the door to entirely new therapeutic possibilities.

The company’s lead program—a first-in-class CDK2 OFF-state inhibitor—has demonstrated significant advantages over traditional approaches:
100x greater selectivity compared to other CDK2 inhibitors, dual mechanism of action: potent inhibition plus targeted degradation, overcoming common resistance mechanisms, and strong potential in cancers with p53 or MYC alterations, where treatment options are limited.

Backed by a seasoned team of drug discovery veterans and active industry partnerships, Type6 is advancing its CDK2 program while building a pipeline to target additional "undruggable" kinases.

While the long-term vision spans oncology, cardiovascular, neurodegenerative, and autoimmune diseases, Type6’s near-term focus is clear: to unlock the kinome’s hidden therapeutic power in aggressive, late-stage cancers.

Type6 Therapeutics

Org chart

Teams

Offices